Senetek PLC Showcases Its Cytokinins at the SMI Group's Key Trends and Issues in Cosmetics & Healthcare Conference
Tuesday March 18, 10:57 am ET
- Presenting the Clinical Data on Kinetin and the Successes of Its Licensees -
NAPA, Calif., March 18 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News), ( www.senetekplc.com ), a healthcare technologies company focused on developing and co-marketing products applicable to the anti-aging markets in key skin care/dermatologicals and sexual dysfunction categories worldwide, today announced that Frank Massino, Chairman & CEO, presented on how to successfully market a cosmeceutical or functional cosmetic at the SMI Conference in London on Key Trends and Issues in Cosmetics and Healthcare.
Attendees at the SMI Conference included pharmaceutical, biotech and cosmetic industry executives from Pfizer, Johnson & Johnson, Glaxo Smith Kline, and Proctor & Gamble. Senetek was selected to speak because many large pharmaceutical and biotech companies are considering introducing new molecules as non-drugs first and then filing for drug indications at a later date. This allows the company to capture revenues early in the life cycle of the product's development. Kinetin, Senetek's patented anti-aging skincare technology, is considered a pioneer in successfully implementing this business strategy.
Mr. Massino presented to the conference clinical data showing the effectiveness of Kinetin and outlined how its licensees, including Revlon, ICN Pharmaceuticals, and The Body Shop, have successfully marketed Kinetin products.
* * *
Visit Senetek PLC's web site: senetekplc.com .
* * *
Senetek PLC Investor Relations Contact:
1-707-226-3900 ext. 102
E-Mail: Pknopick@eandecommunications.com
Safe Harbor Statement:
This news release may contain statements that may be considered "forward- looking statements" under the federal securities laws, including statements concerning the Company's financial stability, its expectations of continued growth and profitability and its intent to expand its overseas business. Forward-looking statements by their nature involve substantial uncertainty and there can be no assurance that actual results or events will not differ materially from those in the forward-looking statements as a result of various factors, including the risks and uncertainties described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 and Quarterly Reports of Form 10-Q for the subsequent calendar quarters of 2002, filed with the Securities and Exchange Commission. In addition, while the Company has attempted to identify in those filings the principal factors that it believes could result in such material differences, there can be no assurance that it has identified all of such factors or all of the ways in which such factors may affect future results or events.
--------------------------------------------------------------------------------
Source: Senetek PLC |
